Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Income from Continuing Operations (2021 - 2025)

Prime Medicine (PRME) has disclosed Income from Continuing Operations for 5 consecutive years, with 47525000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 12.42% year-over-year to 47525000.0, compared with a TTM value of 204838000.0 through Dec 2025, down 4.57%, and an annual FY2025 reading of 204201000.0, down 4.25% over the prior year.
  • Income from Continuing Operations was 47525000.0 for Q4 2025 at Prime Medicine, up from 52832000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 10427000.0 in Q3 2021 and bottomed at 65643000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 44111000.0, with a median of 46643000.0 recorded in 2024.
  • Peak annual rise in Income from Continuing Operations hit 37.54% in 2022, while the deepest fall reached 181.48% in 2022.
  • Year by year, Income from Continuing Operations stood at 62897000.0 in 2021, then soared by 37.54% to 39283000.0 in 2022, then tumbled by 67.1% to 65643000.0 in 2023, then surged by 35.6% to 42276000.0 in 2024, then decreased by 12.42% to 47525000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for PRME at 47525000.0 in Q4 2025, 52832000.0 in Q3 2025, and 52591000.0 in Q2 2025.